A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
about
Eradication therapy for peptic ulcer disease inHelicobacter pylori-positive peoplePeriodontal therapy as adjunctive treatment for gastric Helicobacter pylori infectionPeriodontal therapy as adjunctive treatment for gastric Helicobacter pylori infectionEradication therapy for peptic ulcer disease in Helicobacter pylori positive patientsAntibiotic treatment for Helicobacter pylori: Is the end coming?Chinese Helicobacter pylori vaccine: Solution for an old challenge?The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin.Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan.CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.Helicobacter pylori: the challenge in therapy.Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients.Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A.Nordihydroguaiaretic Acid Disrupts the Antioxidant Ability of Helicobacter pylori through the Repression of SodB Activity In VitroNon-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan.Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis.Efficacy of esomeprazole in treating acid-related diseases in Japanese populationsImprovement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection.Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcersPre-treatment urea breath test results predict the efficacy of Helicobacter pylori eradication therapy in patients with active duodenal ulcers.Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics.Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind studyComparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy.Cost-Effectiveness Analysis of Helicobacter pylori Diagnostic Methods in Patients with Atrophic Gastritis.Usefulness of magnifying narrow-band imaging endoscopy in the Helicobacter pylori-related chronic gastritis.Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication.Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy.Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.Effect of glycine on Helicobacter pylori in vitro.Usefulness of detection of clarithromycin-resistant Helicobacter pylori from fecal specimens for young adults treated with eradication therapy.Evidence-based clinical practice guidelines for peptic ulcer disease 2015.Analysis of Helicobacter pylori genotypes in clinical gastric wash samples.Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.In vitro bactericidal activities of Japanese rice-fluid against Helicobacter pylori strains.In vivo bactericidal activities of Japanese rice-fluid against H. pylori in a Mongolian gerbil model.
P2860
Q24185883-90A24D80-7FAB-491D-89E3-94E47941B9C8Q24186161-181A64A6-1D30-438F-BCC3-A705FA359DDFQ24234785-242CA7BF-BD72-4CFA-9944-651E39774B13Q24246267-432B0FE7-EF3C-44D0-84A0-38058965B514Q26777623-0000FCF7-F8A5-424D-88DC-9BA532FC3897Q28077515-D11CBBEB-490E-4F53-A8D4-590DC594AC60Q33874650-5CDA2825-2150-44E3-ADB5-378D9F26D47FQ33983562-F23236D7-3792-4DAB-8593-7573268CBA1EQ34421492-EC0DEB92-1D24-4532-B92A-37E79373A919Q34583603-EDD187CF-8671-40DB-8D9F-6BAA6E20406AQ34799596-E36949F7-F87F-4A23-B8F4-EA56E0C4F5D6Q35010214-E8AD17D9-1B19-4E1E-8B0D-D461EE45BF2DQ35040382-3EDCDAE8-1987-4207-AD5E-B5435AEBCA48Q35475773-310892A8-10EE-4D67-91C0-437600C52972Q35812525-C14D4DFC-2B36-4881-9B94-6280648BC90DQ35872061-E29F4F89-A410-4BEF-8BC8-23A206E7E2F5Q35987201-B1DE9D95-A9ED-4AE4-8642-CDA79C3314E9Q36177968-F2B8FA1F-882C-43E6-8E13-D288E7A7132AQ36190704-5CCE82B3-5DFE-4581-9D30-60A18150D41CQ36474701-113FB32C-8BCE-4018-B9D1-ECBECDCA0C6AQ36979297-A4655A25-2CE4-45AE-837B-72010FD36D91Q37045762-4B91554E-4CF7-4CC1-95A8-DBAAF02EB875Q37282589-1C3D6E62-3CC0-4242-88FD-5A46B776AA44Q37625226-AD49CCB2-F137-49BB-AF51-66BF204169A7Q37694256-9E255872-755D-474C-BA97-4837096DC2D2Q37832369-6BBFE5EE-2B51-4576-8C4C-24B8B8ABD863Q38219028-EBFB328E-B05B-452A-B5B5-21995C5D45DAQ38502899-72852AB4-9A46-4648-A439-80050919A8E6Q39014376-6B4CE174-5246-4BC3-BBA4-4890EED94143Q39014381-948B0708-4D48-455A-9EF7-7BCA800B6DCEQ39496571-872A71FF-C835-4B33-B89A-852C168A1614Q39496596-8E96739A-5651-4D5A-BA3E-52885432FF69Q39496607-C3626AB9-E724-4839-AF44-BCE37CC3C2D0Q40165615-DA340915-7626-4C68-9411-037BE0F6443DQ40198705-E6EEFA04-2B76-456C-9058-8D3D7FCFEAE4Q40790399-409AB1AA-9421-47F4-A949-E52330ECAE0AQ40812379-86437C2D-778A-4C51-8F79-D428DB967A19Q40892650-E12EA567-159A-4777-959A-09063792FC68Q41890451-280A6311-77DD-414E-BC0F-7E82FEAB25DDQ42092596-D0412DE9-D4CA-49CC-B3D2-06C2170C2F12
P2860
A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
A multicenter, double-blind st ...... apanese peptic ulcer patients.
@en
A multicenter, double-blind st ...... apanese peptic ulcer patients.
@nl
type
label
A multicenter, double-blind st ...... apanese peptic ulcer patients.
@en
A multicenter, double-blind st ...... apanese peptic ulcer patients.
@nl
prefLabel
A multicenter, double-blind st ...... apanese peptic ulcer patients.
@en
A multicenter, double-blind st ...... apanese peptic ulcer patients.
@nl
P2093
P2860
P1433
P1476
A multicenter, double-blind st ...... apanese peptic ulcer patients.
@en
P2093
Kobayashi S
Kuwayama H
Shimoyama T
P2860
P304
P356
10.1046/J.1523-5378.2001.00037.X
P577
2001-09-01T00:00:00Z